Exchange: NYSE·Updated 08:00 PM EDT
EBS logo

EBS Emergent Biosolutions Inc

$6.38
$0.80
(11.14%)
Today
Closed $6.38
$0.03
(0.47%)
After Hours
EarningsNov 2
Mkt Cap$327.12M
Vol2.24M

About EBS

Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It operates through the following segments: Commercial Product Sales, MCM Product Sales, and Services. The Commercial Product Sales segment includes NARCAN products and other commercial products that were sold as part of the travel health business. The MCM Product Sales segment focuses on the Anthrax - MCM products, Smallpox - MCM products and other products. The Services segment consists of the company’s Bioservices offerings. It offers products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats. The company was founded by Fuad El-Hibri on September 5, 1998 and is headquartered in Gaithersburg, MD.
46

Neutral Sentiment

How do you feel about EBS?

filecrux
$EBS Emergent BioSolutions, maker of anthrax and smallpox vaccines and NARCAN, named only an interim CFO: Treasurer Frank Vargo, 43, treasurer since November 2025, replaces CFO of 8+ years Richard Lindahl, and no permanent pick is named. That's at a ~$368.1M company (at $7.18, 16:00 ET Oct 15, 2026) with $589.7M total debt and $139.7M cash at June 30, 2026 (net debt $450.0M); in Q3, $68M cash retired $75M of unsecured bonds. Offset: Lindahl stays as an advisor until he retires March 31, 2027 and helps file the FY2026 10-K. Vargo takes over Jan 1, 2027.
2
1
alwayzwong
$EBS well, totals are in — 2.3 million shares were traded. This is twice the avg daily volume. Significant buying pressure.
8
KnuckleSandwich
$EBS it’s the beginning of the end… or the beginning of the beginning for EBS… See you at 15++
1
4
ComradeKomisar
$EBS Let's see. This year we've had: hanta, ebola, plague. These are all indications for which there is no commercial pre-exposure prophylaxis, so only Uncle Sam can generate demand. Uncle Sam just handed $280M to Regeneron for Inmazeb, is again financing CEPI, it set up its own Ebola vaccine program, and funding for ASPR remains unchanged for over 3 years (inflation is eating it). I think the Trump administration has hit the limit of hard power, and governance realities in the health file, and is removing the choke. Feels like there's more air to breathe here now.
2
ComradeKomisar
$EBS Regeneron just had an Ebola therapeutic option exercized, and now has its contract ceiling raised and expiry extended to 2031.
1
2
Unicorn2020
$EBS Took profit a bit over $1.00 to buy $RARE @ $12.80 (golden opportunity after the gap down) and $ALVO around $5.00-5.15 (FDA decision coming soon). Hope Papa can turn the company around and help push the stock back up to $12 for y’all within 6 months. Wishing you all the best!
5
Cat_on_Deck
$EBS I don't get the panic. This is probably the safest stock to hold now with AI bubble to burst anytime. Gov might cut everything, but they will never cut military and bioterror defense - not in this world. It's existential issue. No way around it.
3
filecrux
$EBS We did a deep dive on Emergent BioSolutions. • CFO exits Dec 31; treasurer interim, no permanent pick • 2026 adj. EBITDA guide low: $130M; H1 alone made $132.0M • $364.7M bonds due Aug 2028 • Next: Nov 2, first 5.25x leverage test Full report linked in the replies.
1
westparktrader
$EBS you have to go long here because after hours is the time to create panic for tomorrow
4
Buchanan7061
$EBS OOHHHHH BABY WE RISING !!!!! Bio defense play - RUSSIA PLAGUE HAPPENING NOW 💰💰💰💰💰💰💰💰💰 CHECK THE NEWS !!!!!
4
KnuckleSandwich
$EBS Contract awards are in bound....good timing with the Russia plague news fueling the momentum!!... See you at 15++.. Might even hit 20 by year-end!
4
WinstonSmith33
$EBS Poor Rich is going into a well-deserved retirement with big pocket of free shares. See you! Bad news: the new CFO will also receive free shares.
1
ComradeKomisar
$EBS EBITDA from q2 '26 will roll off in q2 '27, and will be much lower than a must-have EBITDA baseline of $130M. This speeds up the refinancing timeline to Q4 '26- Q1 '27. That compounds our refinancing risk, and is not permitting the equity re-rate to a level resonable for a company generating sustainable $130M EBITDA. I would expect that overhang to be gone sooner rather than later, between now and March '27. Much earlier than I thought.
3
Cat_on_Deck
$EBS I can read Russian and here's what's happening: "Independent tracking of local Russian social media, localized news reports, and community gossip reveals a stark disconnect between official denials and what was actually happening on the ground in the Irkutsk region. While authorities insist there is no plague, regional activity strongly suggested a heavy containment response was underway, fueling widespread censorship and local panic. Local government figures and municipal administrators actively deleted or edited social media posts that openly discussed a possible plague outbreak. To residents in Shelekhov (the town where Shipilova died) and Irkutsk, this sudden censorship heavily signaled a government cover-up."
2
KnuckleSandwich
$EBS looking like EBS accumulation infection is still spreading.. see you at 15++ on the squeeze!!!
2
Buchanan7061
$EBS Folks the Russia news is just heating up.. we maintained $7 today after a rocket of a day yesterday. EOW PT $10.00 Lessssgoooooooo 💰💰💰💰💰💰💰💰 💸💸💸💸💸💸💸💸 🇷🇺🇷🇺🇷🇺🇷🇺🇷🇺🇷🇺🇷🇺🇷🇺
2
Nuesta
$EBS I clearly got the CYFENDUS successor contract renewal wrong. This stock kills me. Hopefully the awareness that we still live in a dangerous world is getting more attention.
2
Cat_on_Deck
$EBS Accounting issue because old guy with super stressful 10 years wants to retire? So, are they never supposed to retire? Just load up and wait for this to go up again when the next guy in Russia dies.
1
alwayzwong
$EBS lol showing a lot of strength during first 30 mins of the trading day bodes well for the rest of the day. long day coming for the shorty, lol
1
topstockalerts
Emergent BioSolutions shares rose sharply as a suspected pneumonic plague death at Russia’s Irkutsk Anti-Plague Research Institute in Siberia fueled demand for biodefense stocks. U.S. Secretary of State Marco Rubio and the State Department are monitoring the incident and coordinating with the CDC and other agencies, while urging Moscow to provide accurate and timely information. Russian authorities officially attributed the death to pneumonia of unknown etiology and denied a laboratory accident, but local officials activated containment measures, placing at least 197 potential contacts under medical observation or quarantine. The development is particularly relevant to Emergent given its portfolio of approved medical countermeasures. The rally was also supported by strong recent results. $EBS
1

Advertisement|Remove ads.